The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001054 |
Recruitment Status
:
Withdrawn
First Posted
: August 31, 2001
Last Update Posted
: April 4, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To obtain tolerance, safety, and pharmacokinetic data for oral valacyclovir hydrochloride ( 256U87 ) in HIV-1 infected children with herpes simplex virus infections ( cold sores ) and/or varicella / zoster virus infections ( chicken pox / shingles ).
Varicella and zoster are common problems in HIV-infected children. It is believed that chronic oral therapy with acyclovir may result in subtherapeutic concentrations of acyclovir, resulting in resistance to that drug. Valacyclovir hydrochloride, which converts to acyclovir in the body, increases acyclovir bioavailability by 3-5 fold.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Herpes Simplex HIV Infections Chickenpox | Drug: Valacyclovir hydrochloride | Phase 1 |
Varicella and zoster are common problems in HIV-infected children. It is believed that chronic oral therapy with acyclovir may result in subtherapeutic concentrations of acyclovir, resulting in resistance to that drug. Valacyclovir hydrochloride, which converts to acyclovir in the body, increases acyclovir bioavailability by 3-5 fold.
In the first cohort, patients with stable herpes simplex virus receive valacyclovir hydrochloride at 1 of 2 doses, depending on body surface area (BSA), for 10 days. If acceptable safety is seen at this dose level, a second cohort of patients with stable herpes simplex virus receive a higher dose, depending on BSA, for 10 days. A third cohort of patients with varicella or zoster receive a selected dose based on results from the previous cohorts.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Valacyclovir HCl in HIV-1 Infected Children With Herpes Simplex Infections or Varicella/Zoster Infections |
Actual Study Completion Date : | January 2001 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years to 12 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Antiretrovirals.
- PCP prophylaxis.
- IVIG, G-CSF, and erythropoietin.
Concurrent Treatment:
Allowed:
- Transfusions.
Patients must have:
- Localized mucocutaneous herpes simplex OR undisseminated varicella or zoster.
- HIV positive. NOTE: Varicella patients must NOT have AIDS.
- CD4 count >= 100 cells/mm3 (herpes simplex or zoster patients) OR >= 250 cells/mm3 (varicella patients).
- BSA > 0.6 m2.
- Ability to swallow solid dosage formulations.
Prior Medication:
Allowed:
- Prior VZV immune globulin and/or IVIG.
- Antiretrovirals if at a stable dose for at least 14 days.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Clinical evidence of pneumonitis.
- Severe abdominal pain or back pain.
- Encephalopathy.
- Hemorrhagic varicella.
- Zoster involving ophthalmic branch of trigeminal nerve.
- Severe gastrointestinal disorder.
Concurrent Medication:
Excluded:
- Agents with potential activity against HSV or VZV, such as acyclovir, famciclovir, ganciclovir, foscarnet, and sorivudine.
- Probenecid.
- Aspartamine within 48 hours prior to pharmacokinetic samplings.
Patients with the following prior conditions are excluded:
- Grade 2 creatinine value within the past 30 days.
- Grade 3 hematologic or hepatic values within the past 30 days.
- Prior hypersensitivity and/or allergic reaction to acyclovir.
- Grade 3 or 4 mental status changes within the past 30 days.
Prior Medication:
Excluded:
- Acyclovir within 1 week prior to study entry.
- Steroids within 4 weeks prior to onset of varicella lesions.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001054
Study Chair: | Keller MA | ||
Study Chair: | Bryson Y | ||
Study Chair: | Gershon A |
Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00001054 History of Changes |
Other Study ID Numbers: |
ACTG 253 11230 ( Registry Identifier: DAIDS-ES ) |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | April 4, 2012 |
Last Verified: | April 2012 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Herpes Zoster AIDS-Related Opportunistic Infections Herpes Simplex Acquired Immunodeficiency Syndrome |
AIDS-Related Complex valacyclovir Chickenpox |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Herpes Simplex Chickenpox Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Herpesviridae Infections DNA Virus Infections Skin Diseases, Viral Skin Diseases, Infectious Skin Diseases Valacyclovir Acyclovir Antiviral Agents Anti-Infective Agents |